Barri Blauvelt founded Innovara, Inc., a global business and management development firm in late 1983, dedicated to providing highly customized, results-oriented services to health care industries worldwide. Mrs. Blauvelt and her company service clients mainly in three areas: commercial organizational talent; business development, new product strategy and commercialization; and medical thought leadership development.
She has led Innovara to become the leading company in global medical thought leadership development, and one of the top five in the world in development of health care commercial personnel. She heads Innovara’s rapidly growing role to help to launch new drugs, particularly targeted at pharma (NCE, biosimilars and generics), devices, biotech, diagnostics, consumer health care and start- up medicine and technology-based businesses. Innovara clients number among the world’s leading pharmaceutical, medical device and diagnostics companies, as well as leading research-based academic medical institutions, health care service providers/payer organizations and NGOs. She also holds adjunct faculty positions in business management and public health, as well as is on the (US) President’s Cancer Panel.
Raised and educated internationally (Asia, Canada, Europe, US), prior to forming Innovara, Mrs. Blauvelt worked in international patent and trademark law with the (then) leading global IP law firm, in corporate public affairs with Exxon Corporation, in sales and in marketing management positions with Pfizer in the USA, as head of Far East, for Medical Products of Cyanamid Corporation (Lederle and Davis & Geck Divisions), eventually becoming of a manager of global marketing, in charge of both ethical and consumer health care products for Lederle Laboratories and Lederle Consumer Health Care products, and is best known for launching brands such as Centrum to the world. She also was Chairman of the Asia Subcommittee of PhRMA (Washington DC) and a representative for the US/China Trade Commission (in cooperation with US and PRC governments). While working at Cyanamid, she also was the first person to negotiate successfully for a majority-held foreign pharmaceutical company in Korea and tripled other Asian business within 2 years.
Mrs. Blauvelt has an undergraduate degree in international education and pre-law and holds an MBA in marketing from the Graduate School of Business, Columbia University (New York City), where she also studied law and post-doctoral level Management Sciences. In addition to heading Innovara, she is guest or co-faculty at several other top graduate schools of business and medicine/public health in the USA and around the world. Most recently, she also has been invited to the (US) President’s Cancer Panel, focusing on ethnicity of cancer to help guide US health policies. She is Chair of Women in High Places (WHIP), the exclusive network of the women globally in health care medicine, policy, advocacy and industry (esp. cancer and diabetes). Finally, she works in affiliation with the medical thought leaders globally in oncology, diabetes, rheumatology, transplantation, preventive medicine (vaccines, biological), COPD/Respiratory disease, diabetes, transplantation, infectious disease, liver disease/hepatology, endocrinology, immunology, CV and other chronic diseases.
Mrs. Blauvelt is a published author of studies from medical horizon scanning to benchmarking best medical and industry practices, public policy and advocacy, as well as studies focusing on cancer, diabetes and other chronic health care control. In public health policy research, she often partners with U. of Massachusetts, Johns Hopkins and Harvard U. Schools of Public Health and other leading international Institutes involved in global health. On the industry side, she has authored major industry-wide benchmarking studies on best practices in new product commercialization (based upon an independent Innovara study done every 3 years) and on marketing management, published in leading industry publications such as Pharmaceutical Executive and MedAdNews. She was a major contributor to the latest President’s Cancer Panel Annual Report (http://deainfo.nci.nih.gov/advisory/pcp/annualReports ) issued June 2011. Her latest industry benchmarking study, Excellence in Specialty Medicine, will be published in early 2012. A “globalist”, she is frequently invited to speak at industry and government conferences both in the United States and overseas.
105 Middle St, Hadley,
MA 01035, US
+1 413 387 6188
+1 413 387 6772